{"organizations": [], "uuid": "ffd21d1d1693d1bf3ef267b7774a720acbeb23b4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-catalyst-biosciences-announces-man/brief-catalyst-biosciences-announces-manufacturing-agreement-with-agc-biologics-for-subcutaneous-factor-ix-product-cb-2679d-idUSFWN1QG0OX", "country": "US", "domain_rank": 408, "title": "BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.208, "site_type": "news", "published": "2018-02-26T21:12:00.000+02:00", "replies_count": 0, "uuid": "ffd21d1d1693d1bf3ef267b7774a720acbeb23b4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-catalyst-biosciences-announces-man/brief-catalyst-biosciences-announces-manufacturing-agreement-with-agc-biologics-for-subcutaneous-factor-ix-product-cb-2679d-idUSFWN1QG0OX", "ord_in_thread": 0, "title": "BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "agc biologics for subcutaneous factor ix product cb", "sentiment": "negative"}, {"name": "reuters) - catalyst biosciences inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}, {"name": "agc biologics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Catalyst Biosciences Inc:\n* CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D\n* CATALYST BIOSCIENCES INC - PLAN TO INITIATE A PHASE 2B STUDY OF CB 2679D IN INDIVIDUALS WITH SEVERE HEMOPHILIA B IN Q3 OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T21:12:00.000+02:00", "crawled": "2018-02-27T14:39:16.127+02:00", "highlightTitle": ""}